NCT Number: NCT03496688
Comparative Results of Six Biomaterials Used in Two-stage Maxillary Sinus
Objectives: The aim of the study was to compare histological and histomorphometric results of six bone substitute materials used as graft in two-stage maxillary sinus augmentation model, after 6-month-healing.
Looking for future studies?
Notify MeKey information
Conditions
Age range
33 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
Materials and Methods:
A two-stage sinus augmentation was carried out in six patients using mineralized solvent-dehydrated bone allograft (MCBA), freeze-dried mineralized bone allograft (FDBA), anor-ganic bovine bone (ABB), equine-derived bone (EB); synthetic micromacroporous biphasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hydroxyap-atite (HA-β-TCP 30/70), or bioapatite-collagen (BC).
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
patients healthy, absence of systemic pathologies (ASA class I), non-smokers, good oral hygiene, not pregnant or lactating, absence of painful symptoms and associated inflammatory or osteolytic pathologies, maxillary partial edentulism involving the premolar/molar areas, residual bone height between the sinus floor and alveolar ridge ranging from 2 to 4 mm, as measured on computerized tomography (CT) scan.
-
Exclusion criteria
-
Treatment and study plan
Primary outcomes
-
to perform biopsies from each six augmented site using to compare, histologically and histomorphometrically, the percentages of newly formed bone, residual grafted material, and marrow spaces.
Time frame: 6 month-healing after surgery
After 6 months clinical and radiographic examinations were undertaken and each patient was reappointed for biopsy at the time of implant placement in the same location. Under local anesthesia, a full thickness flap was raised, a biopsy was performed using a 3.5 mm tre-phine bur under sterile saline solution irrigation, guided by the radiographic/surgical template in the selected implant site. A total of six bone samples was retrieved from the occlusal aspect to the alveolar crest, one from each augmented site to compare histologically and histomorphometrically the different materials.
Sponsors and collaborators
Lead sponsor
University of Roma La Sapienza
Other
Registry information
Official study title
Comparative Histological and Histomorphometric Results of Six Biomaterials Used in Two-stage Maxillary Sinus Augmentation Model After 6-month-healing
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2017
- First posted
- Apr 12, 2018
- Registry last updated
- Apr 12, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
NCT05698316
Age Related Macular Degeneration, Atrophy
Nantes, France
View Trial DetailsEfficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
NCT05156320
Anti-myostatin, Atrophy
Birmingham, Alabama, United States
View Trial DetailsAn Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
NCT03921528
Atrophy, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsQuantifying Quadriceps Atrophy Following Tibial Plateau Fracture
NCT02781623
Atrophy, Fractures, Bone
New York, United States
View Trial Details